Observational analysis identified long non-coding RNAs as potential targets for stemness-directed therapy, indicating significant metabolic reprogramming in cancer stem cells.
Key Points
High-stemness subtype exhibited profound metabolic reprogramming, enhancing cancer aggressiveness.
A robust prognostic model was constructed, predicting outcomes based on unique long non-coding RNAs per cancer type.
The integration of bulk transcriptomic data with single-cell analysis enabled a comprehensive understanding of cancer stem cells.
Research highlights the therapeutic vulnerabilities associated with regulatory long non-coding RNAs in tumor progression.